Table 2.
Performance Statistics for CEA and Methylated BCAT1/IKZF1 ctDNA
| CEA | Qualitative ctDNAa | Quantitative ctDNAb | |
|---|---|---|---|
| No. | 131 (47 with recurrence) | 144 (50 with recurrence) | 144 (50 with recurrence) |
| Sensitivity, % | 31.9 (22.8‐36.6) | 66.0 (55.3‐74.0) | 66.0 (57.1‐69.3) |
| Specificity, % | 96.4 (91.4‐99.0) | 90.4 (84.7‐94.7) | 97.9 (93.2‐99.6) |
| Likelihood ratio (+) | 8.94 (2.64‐38.04) | 6.89 (3.62‐13.89) | 31.0 (8.35‐183.81) |
| Likelihood ratio (–) | 0.706 (0.640‐0.845) | 0.376 (0.275‐0.528) | 0.347 (0.308‐0.460) |
| Odds ratio | 12.7 (3.43‐46.69) | 18.3 (7.44‐45.20) | 89.3 (19.56‐407.53) |
Abbreviations: BCAT1, branched‐chain amino acid transaminase 1; CEA, carcinoembryonic antigen; ctDNA, circulating tumor DNA; IKZF1, Ikaros family zinc‐finger 1 protein.
All patients with recurrences (n = 50) and all patients without recurrences on the basis of 2 serial images (n = 94) were included. The values within parentheses are 95% confidence intervals.
a
The threshold was 0 pg per sample.
b
The threshold was 12.8 pg per sample.